Jennifer Humes
Vermogen: 4 M $ op 31-07-2026
Vermogen: 4 M $ op 31-07-2026
Jennifer Humes is Chief Accounting Officer at Roivant Sciences Ltd. and Roivant Sciences, Inc., starting in 2025.
Ms. Humes worked at JPMorgan Chase & Co. from 2016 to 2024, serving as Controller-Global Investment Banking in 2024.
Ms. Humes completed undergraduate education at the University of St. Thomas.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-06-2026 | 109.782 ( 0,02% ) | 4 M $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ROIVANT SCIENCES LTD. | Comptroller/Controller/Auditor | 20-02-2025 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Comptroller/Controller/Auditor | 20-02-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | 01-12-2024 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
JPMorgan Chase & Co.
JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
Roivant Sciences Ltd.
Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
University of St. Thomas
University of St. Thomas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau